TIL therapies are returning to the forefront of solid tumor treatment to take advantage of their inherent ability to target heterogeneous antigens and survive in the hostile tumor microenvironment. Now with advances in TIL selection through the benchmarking of optimal biomarkers, streamlined manufacturing processes to improve turnaround time and cost of goods, and commercialization discussions on the horizon... it is time to get caught up to speed on the fast-evolving TIL approach.
Join the TIL Therapies Summit; the only industry-focused event dedicated to TIL therapies this October to network and learn from the pioneers of Iovance, Turnstone Biologics, MD Anderson, Achilles Therapeutics and Obsidian Therapeutics.
Promising comprehensive content critical to your clinical and commercial development including:
- QC and potency assay development to bridge clinical data and remove variability
- Biomarker and target identification to improve T cell selection
- Cutting-edge genetic engineering approaches to enhance TIL function
Don't miss out on the chance to collaborate with the leaders of TIL treatment, improve your competitive intelligence and capitalize on the cell therapy approach which holds the most promise for solid tumors.
19-21 October, 2021
9.30am-4:30pm EST | 6.30am-1:30pm PST
Drug Developers (Earlybird rates, focus day and workshops available): USD 2099.0,
Academic (Earlybird rates and workshops available): USD 1599.0,
Service Providers (Earlybird rates and workshops available): USD 2599.0
Speakers: Andrew Weinberg, Chief Scientific Officer, AgonOx, Ed Samuel, Senior Vice President, Technical Operations, Achilles Therapeutics, Brad Nelson, Director and Distinguished Scientist, BC Cancer Deeley Research Centre, Friedrich Graf Finckenstein, Chief Medical Officer, Iovance Biotherapeutics, Jan Ter Meulen, Chief Scientific Officer, Obsidian Therapeutics, Caroline Breitbach, Vice President, R and D Programs and Strategy, Turnstone Biologics
Time: 09:30 - 16:30